(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 September 2009 (17.09.2009)

PCT

(10) International Publication Number
WO 2009/114373 A1

(51) International Patent Classification:
A61K 31/4985 (2006.01) *A61P 27/02* (2006.01)

(21) International Application Number:
PCT/US2009/036119

(22) International Filing Date:
5 March 2009 (05.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/035,073 10 March 2008 (10.03.2008) US

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS** [FR/FR]; 174 avenue de France, F-75013 Paris (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OLIGINO, Thomas** [US/US]; c/o Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **HAHN, Chang** [KR/US]; c/o Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **GILLESPY, Timothy A.** [US/US]; c/o Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **DHARANIPRAGADA, Ramalinga** [US/US]; c/o Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US). **MATZKIN, Ellen** [US/US]; c/o Sanofi-Aventis U.S. Inc., 1041 Routes 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(74) Agents: **BOLCSAK, James, W.** et al.; Sanofi-Aventis U.S. Inc., 1041 Route 202-206, Mail Code: BWD-303A, Bridgewater, New Jersey 08807 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: TREATMENT FOR OCULAR-RELATED DISORDERS



(I)

(57) **Abstract**: A treatment for ocular related disorders, such as macular degeneration, and preferably age-related macular degeneration, diabetic retinopathy, and diabetic macular edema is disclosed, using a compound of Formula I.

WO 2009/114373 A1